DiaMedica Therapeutics (DMAC) Revenue (2018)
DiaMedica Therapeutics' (DMAC) quarterly Revenue came in at $500000.0 in Q3 2018.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Revenue (2018) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Revenue for 1 consecutive years, with $500000.0 the latest figure, recorded in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.59 Bn | 193.60 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 178.73 Bn | 175.55 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 131.17 Bn | 123.32 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.73 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 61.01 Bn | 55.82 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.40 Bn | 48.27 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.49 Bn | 30.18 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.64 Bn | 30.35 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.66 Bn | 29.66 Bn | 1.16 Mn | 1.44 Mn |
| 10 | DiaMedica Therapeutics | 351.39 Mn | 351.39 Mn | - | - |